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Abstract
Background: Smokeless tobacco is often referred to as a major contributor to oral cancer. In
some regions, especially Southeast Asia, the risk is difficult to quantify due to the variety of
products, compositions (including non-tobacco ingredients) and usage practices involved. In
Western populations, the evidence of an increased risk in smokeless tobacco users seems unclear,
previous reviews having reached somewhat differing conclusions. We report a detailed quantitative
review of the evidence in American and European smokeless tobacco users, and compare our
findings with previous reviews and meta-analyses.
Methods: Following literature review a meta-analysis was conducted of 32 epidemiological studies
published between 1920 and 2005 including tests for homogeneity and publication bias.
Results: Based on 38 heterogeneous study-specific estimates of the odds ratio or relative risk for
smokeless tobacco use, the random-effects estimate was 1.87 (95% confidence interval 1.40–2.48).
The increase was mainly evident in studies conducted before 1980. No increase was seen in studies
in Scandinavia. Restricting attention to the seven estimates adjusted for smoking and alcohol
eliminated both heterogeneity and excess risk (1.02; 0.82–1.28). Estimates also varied by sex
(higher in females) and by study design (higher in case-control studies with hospital controls) but
more clearly in studies where estimates were unadjusted, even for age. The pattern of estimates
suggests some publication bias. Based on limited data specific to never smokers, the random-effects
estimate was 1.94 (0.88–4.28), the eight individual estimates being heterogeneous and based on few
exposed cases.
Conclusion: Smokeless tobacco, as used in America or Europe, carries at most a minor increased
risk of oral cancer. However, elevated risks in specific populations or from specific products cannot
definitely be excluded.
Background
Oral cancer, histologically most frequently squamous-cell
carcinoma, includes malignant neoplasms of the lip,
tongue, palate, gum, piriform sinus, floor of the mouth,
pharynx, tonsils, salivary glands and unspecified parts of
the mouth [1]. It is the eighth and 14th most incident can-
cer worldwide in men and women, respectively [2]. Age-
standardised mortality rates (per 100,000 per year) differ
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regionally, ranging (in 2001) from 2.4 in Sweden to 21.2
in Hungary. Trends differ also, with, in the past two dec-
ades, decreases in the US, Finland and Sweden, and
increases in Hungary, the Czech Republic, Germany and
Norway [3,4]. US mortality rates are higher in blacks than
whites, and prevalence is greater in areas with a high pro-
portion of Asians [5].
Among specific risk factors commonly discussed are alco-
hol, solar radiation, genetic predisposition, and tobacco
(smoking and smokeless). Smoking has been estimated to
pose twice as high a risk of oral cancer as does smokeless
tobacco use [6]. Except for the exact magnitude of the risk
difference, this is rarely questioned, and usually attributed
to the lack of combustion products from smokeless
tobacco [7]. Smokeless tobacco products are traditionally
classified as snuff or chewing tobacco [8]. In Europe and
North America usage is mostly oral, while nasal use of
finely ground "dry snuff" has become rare [9]. In the US,
finely cut "moist snuff" or chewing tobacco is held (or in
the case of the latter chewed) in the gingival buccal area.
In Scandinavia snuff (or snus in Sweden) is generally
placed under the upper or lower lip.
Oral tobacco has long been referred to as a major contrib-
utor to oral cancer incidence. In line with International
Agency for Research on Cancer [IARC] monograph 37
[10], the US Surgeon General [11] concluded in 1986 that
"the association between smokeless tobacco use and can-
cer is strongest for cancers of the oral cavity" and that "evi-
dence for an association between smokeless tobacco use
and cancers outside the oral cavity in humans is sparse."
The conclusion for oral cancer was based on only a few,
mainly quite small studies that provided quantitative
data.
Later Gross et al. [12] meta-analysed 12 US studies con-
ducted between 1952 and 1993. They computed a ran-
dom-effects relative risk of 1.74 (95% confidence interval
[CI]: 1.32 to 2.31) and concluded that "a relative risk < 2.0
may be considered to represent a weak association
because of the biases and confounders that tend to affect
observational studies." While the individual relative risk
[RR] estimates ranged from 0.99 to 4.44, those in 12 stud-
ies in Southeast Asia ranged from 2.2 to 39.19, corre-
sponding to an overall estimate of 8.94 (95% CI:
5.26–15.18). Gross et al. concluded that "the studies in
Southeast Asia suggest a strong relationship between the
risk of oral cancer and the use of chewing tobacco. The
tobacco chewed in these countries was often mixed with
some other substances, such as betel quid and areca nut.
It is still unclear whether it is the tobacco or the substance
added [that] plays the major role." The authors also
reported estimates from four studies in other regions, two
in Europe and two in Latin America. These ranged from
0.67 to 1.40, more resembling the US than the Southeast
Asian findings.
In 1996 Pershagen [9] published a wide-ranging review
on exposure and health aspects of smokeless tobacco.
With respect to oral cancer he stated that "methodological
limitations in the studies make it difficult to interpret the
findings." Nevertheless, based on six case-control studies
from Sweden and the US, and with particular emphasis on
the study of Winn et al. [13], which he considered to be
the most conclusive, Pershagen inferred that "habitual use
of oral tobacco can increase the risk of oral cancer." He
cited an odds ratio [OR] of 4.2 for the Winn et al. study.
However, this estimate refers to only a subgroup (white
nonsmoking women). In contrast, the estimate based on
all the available data was lower at 2.7 (1.8–3.9).
In a toxicological and epidemiological assessment of the
health risks of snuff dipping, Nilsson [14] concluded that
"although a small risk cannot be excluded, the use of
smokeless tobacco products low in TSNA which now are
available on the market entails a risk that at any rate is
more than 10 times lower than that associated with active
smoking." He pinpointed "a wide discrepancy" between
the estimated cancer risk found in studies conducted in
Sweden and the US. The US data were drawn mostly from
the Winn et al. study [13]. For Sweden Nilsson concluded
that although about "20% of all grown-up Swedish males
use moist snuff, it has not been possible to detect any sig-
nificant increase in the incidence of cancer of the oral cav-
ity or pharynx – the prevalence of which by international
standards remains low in this country." At the ecological
level the situation is similar in the US. West Virginia has
the highest consumption of smokeless tobacco of all US
states, but below average oral cancer incidence rates [15].
Rodu and Cole [16] conducted a meta-analysis on smoke-
less tobacco use and upper respiratory tract cancer based
on 21 publications. Although the available data about
tobacco type are sparse and ambiguous in some reports,
the authors attempted separate analyses. For oral and pha-
ryngeal cancer they estimated a relative risk of 1.1
(0.8–1.6) for chewing tobacco, 0.7 (0.4–1.2) for moist
snuff, 4.0 (2.7–5.9) for dry snuff and 1.5 (1.1–2.0) for
unspecified smokeless tobacco use. They concluded that
"the use of moist snuff and chewing tobacco imposes
minimal risks for cancers of the oral cavity and other
upper respiratory sites..."
Critchley and Unal [17] conducted a narrative literature
review of studies with a total sample size of at least 500
participants, including studies in both Western and
Southeast Asian countries. They concluded that the study
of Winn et al. [13] "remains the strongest evidence for an
association of ST use with oral cancers in the US, althoughBMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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it is limited to women and was carried out many years
ago." They based this conclusion on the same OR estimate
of 4.2 that Pershagen [9] cited. For Scandinavian studies
the reviewers concluded that "although these findings are
consistent with no effect, the studies do not have suffi-
cient power to detect a moderately raised OR." Overall,
according to Critchley and Unal, there exists "...a substan-
tial risk of oral cancers in India" while for the US and
Scandinavia "most recent studies...are not statistically sig-
nificant, but moderate positive associations cannot be
ruled out due to lack of power."
The information we examined suggests at most a minor
increased risk of oral cancer associated with smokeless
tobacco use in Western countries. Elsewhere, products
used are likely to differ in toxicity, and their associated
risk, especially in Southeast Asia, is difficult to quantify
due to the variety of products, compositions (including
non-tobacco ingredients) and usage practices involved.
Our objective was to conduct a detailed analysis of pub-
lished evidence on the association of American and Euro-
pean smokeless tobacco and oral cancer, and to calculate
a pooled effect estimate. Compared with the reviews of
Rodu and Cole [16] and Critchley and Unal [17] we
aimed to include more studies, and carry out a more
detailed quantitative analysis, including random-effects
and fixed-effect meta-analyses and an investigation of het-
erogeneity.
Methods
Study identification and selection
RW identified reports from a systematic search, not lim-
ited by period or language, of MEDLINE, EMBASE, CAN-
CERLIT and TOXLINE through March 2005. The main
searches used combinations of the terms "smokeless
tobacco", "chewing tobacco", "snuff", and "snus" for
exposure, and "oral cancer" and "mouth neoplasms" for
outcome. Specific oral cancer sites corresponding to ICD-
10 codes C00 to C14 [1] were also searched for. Further
articles were identified from reference lists in individual
papers and reviews.
All reports had to satisfy the following Inclusion criteria:
published in peer reviewed journal or publicly available,
based on research on humans, of cohort or case-control
design, study location specified, any form of oral cancer as
the outcome, and chewing tobacco, orally used moist
snuff or unspecified smokeless tobacco as the exposure.
They also had to satisfy the Exclusion criteria: sample
included in a more complete or recent study, conducted in
an Asian population, no control group, inappropriate
design (case report, qualitative study or review/meta-anal-
ysis), insufficient power (less than five expected exposed
cases), appropriate risk estimates and CIs not reported
and cannot be computed from the available data.
Having completed this process, RW then compared the
selected studies with those of a previous unpublished
review conducted in 2002 by PNL based on MEDLINE,
reference lists and reviews.
Data extraction
From each report details were abstracted relating to the
study (design, period, region, population, sample selec-
tion, size, and matching criteria), the exposure (method
of assessment, type of smokeless tobacco investigated,
exposure doses and durations considered), the outcome
(type and location of oral cancer and method of diagno-
sis), and issues relating to analysis (type of effect measure,
analysis methods, stratification variables, and adjustment
factors).
To avoid bias, it would be advantageous to restrict atten-
tion to estimates of effect size (OR or RR) and of precision
(95% CI) based on subjects who have never smoked.
However, such results are rarely available, and are often
based on very limited numbers of cases. Our main analy-
ses are therefore based on estimates derived from the
whole population, smokers and nonsmokers combined,
except for studies where the only available results are spe-
cifically for smokers or for nonsmokers. However, esti-
mates of effect size and precision specifically for never
smokers were also extracted for an additional analysis (see
the end of the results section).
Where possible, separate estimates were obtained for male
and female subjects and for different types of smokeless
tobacco; chewing, snuff or smokeless (unspecified or
chewing/snuff). Estimates for ever exposure were pre-
ferred to estimates for current exposure. Adjusted esti-
mates were preferred to crude estimates and where
multiple adjusted estimates were available, that adjusted
for the most potential confounding variables was used.
In many studies, the required estimates of effect size and
precision were not given by the authors and had to be esti-
mated. Crude estimates were derived from the relevant 2
× 2 table using standard methods, with, where necessary,
numbers estimated from proportions given numerically
or graphically and/or combined over types of oral cancer
or levels of exposure. Independent crude estimates were
combined over strata by fixed-effect meta-analysis [18] to
obtain estimates adjusted for the stratifying variables.
Non-independent adjusted estimates were combined over
exposure levels or types of oral cancer using a method that
accounts for the correlation of estimates with a common
baseline group [19-21]. In a few studies where informa-
tion was available on chewing and on snuff but not on
joint use, approximate estimates for combined smokeless
use were obtained assuming that no-one used both prod-
ucts.BMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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Meta-analysis
For effect size estimate, the standard error of its logarithm
was calculated from its reported or estimated CI, assum-
ing that the effect size was log-normally distributed. The
logarithms of the effect sizes and their corresponding
standard errors formed the data points for fixed-effect and
random-effects meta-analyses[18]. Separate sets of meta-
analyses were carried out for chewing tobacco, for snuff
and for overall smokeless tobacco use (both from studies
where only estimates for unspecified use were available
and from studies where the estimate was derived from the
separate data for chewing tobacco and snuff). A fourth set
of meta-analyses, referred to as "all" types in the tables,
used the smokeless tobacco estimates where available and
otherwise the estimates specifically for chewing tobacco
or for snuff. Within each set, meta-analyses were carried
out based on all the estimates, regardless of the extent of
confounding adjustment, and on estimates that were
unadjusted or adjusted for various combinations of smok-
ing, alcohol, age and social status. For each analysis,
within-group heterogeneity was assessed by the chi-
squared test of homogeneity [22] and by the I2 statistic
[23].
For selected meta-analyses, a forest plot is shown. Each
estimate is shown as a rectangle, with its area proportional
to its weight. The CI is indicated by a horizontal line. The
data are plotted on a logarithmic scale so that the estimate
is centred in the CI. Also shown in the plot are the actual
values of the estimate and its CI and weight. Results from
a random effects meta-analysis are also shown. The com-
bined estimate is presented as a diamond with the width
corresponding to the CI, and the estimate as the centre of
the diamond.
For the "all" types set of estimates, sensitivity analyses
were carried out by eliminating those estimates that were
only for smokers or only for nonsmokers, and also by
replacing those estimates that were calculated approxi-
mately assuming that there were no joint users of chewing
tobacco and snuff by estimates for chewing tobacco in US
studies and for snuff in Swedish studies. Heterogeneity
was also investigated further, separately for estimates
unadjusted for any factor and estimates adjusted for
smoking. Subgroups were defined a priori by type of
smokeless tobacco, sex, study design, study location,
study period, and by whether or not the estimate was
reported by the author or was derived by us. Between-sub-
group heterogeneity was assessed by a chi-squared test
[24]. To describe the contribution of the investigated sub-
groups further, the between-subgroup chi-squared was
expressed as a percentage of the total chi-squared.
Additional meta-analyses were carried out for the set of
estimates for smokeless tobacco use among never smok-
ers.
Publication bias was assessed by a funnel plot, in which
the logarithm of the effect size was plotted against its pre-
cision [25,26].
Results
1313 potentially relevant studies were identified by the
literature search, but only 63 appeared possibly of value
from initial assessment. These underwent more detailed
examination and 32 met the inclusion and exclusion cri-
teria. Of the 31 studies that did not, ten were excluded due
to insufficient quantitative information [14,27-35], five to
lack of a control group [36-40], two to limited
power[41,42], three to the outcome not being oral cancer
[43-45], and three to non-Western smokeless tobacco [46-
48]. Two reports [49,50] were letters commenting on
studies already rejected for other reasons, and two were
reviews [51,52]. Four publications [53-56] referred to
studies which were more recently or more completely or
adequately covered in other publications [13,57-59].
Extracted data
Table 1, sorted on publication year, gives details of the 29
case-control and three cohort studies considered in this
analysis. The reports were published between 1920 and
2005. 25% of the studies were published up to 1970 and
25% after 1994. Most studies (no = 24) were conducted in
the USA, with three in Sweden (studies 19, 27, 29), and
one each in Puerto Rico (study 7), the UK (study 9), Brazil
(study 18), Denmark (study 26), and Norway (study 31).
Not all studies were primarily concerned with the rela-
tionship between smokeless tobacco and oral cancer.
Consequently, study-specific inclusion and exclusion cri-
teria varied, as did criteria for matching of controls. Of the
29 case-control studies, seven (studies 3, 10, 11, 14, 15,
25, 28) selected controls without smoking-related dis-
eases, five (2, 7, 18, 19, 23) selected controls without any
cancer or without oral and other specific cancers, nine (1,
4, 5, 6, 8, 12, 13, 17, 24) selected patient controls without
oral cancer, and eight (9, 16, 20, 21, 26, 27, 29, 30)
selected population controls essentially without restric-
tion.
Table 2 shows the cancer sites considered in the 32 stud-
ies. The definitions of sites were often imprecisely stated,
so the table must be regarded as an approximation.
Table 3 contains the main results (i.e. those for smokers
and nonsmokers combined where possible) for the 32
studies. Further estimates relating to the site where the
smokeless tobacco was held are given elsewhere[60]. MostB
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) Table 1: Study overview (included studies).
Study First author, year of 
publication
Region Study perioda Designb Sex Case definition 
(or at risk populationc)d
Controls 
(or years of follow-upc)
Matching factorse
1 Broders 1920 [74] USA up to 1920 CCH M+F NS No lip cancer NS
2 Moore 1953 [57] USA 1951–1952 CCH M 50+ years No cancer NS
3 Wynder 1957 [58] USA up to 1957 CCH Mf NS Benign diseases, lymphoma, skin and gastrointestinal 
cancer
Age, rel, ins, ses
4 Peacock 1960 [93] USA 1952–1958 CCH M+F With data on tobacco habits No oral cancer Sex, race, ins
5 Vogler 1962 [62] USA 1956–1957 CCH M+F Incident and prevalent No oral cancer None
6 Vincent 1963 [94] USA up to 1963 CCH Mg Incident Successive gastrointestinal patients Age
7 Martinez 1969 [95] Puerto Rico 1966 CCH/P M+F Incident in 1966 Patients without cancer and community controls Age, sex
8 Keller 1970 [75] USA 1958–1962 CCH M Discharged with complete records No oral cancer Age, hosp, time
9 Browne 1977 [96] UK 1957–1971 CCP M+F NS Community controls Age, sex, occ, area
10 Williams 1977 [97] USA 1969–1971 CCH M+F Incident, Third National Cancer Survey No tobacco- or alcohol-related cancers None
11 Wynder 1977 [98] USA 1969–1975 CCH M Histologically confirmed No tobacco-related diseases Age, race, area
12 Westbrook 1980 [63] USA 1955–1975 CCH F Incident Unstated hospital controls Age, time
13 Winn 1981 [13] USA 1975–1978 CCH F Incident and death certificate No oral cancer or mental disease Age, race, type, area
14 Wynder 1983 [99] USA 1977–1980 CCH Mf Histologically confirmed No tobacco-related diseases Age, race, hosp, ins
15 Stockwell 1986 [65] USA 1982 CCP M+F Cancer registry 1982 Melanoma or endocrine cancer None
16 Blot 1988 [100] USA 1984–1985 CCP M+F Incident Population controls Age, sex, area, race
17 Spitz 1988 [101] USA 1985–1987 CCH M+F Registered 1985–1986, completed questionnaire, 
histologically confirmed with squamous cell 
carcinoma of defined sites
No squamous cell carcinoma Age, sex
18 Franco 1989 [102] Brazil 1986–1988 CCH M+F Incident, not lip or salivary glands No cancer or mental disorder Age, sex, area, time
19 Blomqvist 1991 [103] Sweden up to 1991 CCH M+F NS No cancer Age, sex
20 Maden 1992 [104] USA 1985–1989 CCP M Squamous cell, 18–65 years, with residential 
telephone
Population controls Age, time
21 Sterling 1992 [67] USA 1986 CCP M+F Registered in National Mortality Followback Study 
1986, age 25+ years
Population controls None
22 Zahm 1992 [72] USA 1954–1980 Cohort M US veterans who returned questionnaire on tobacco 
use in 1954 or 1957
Mortality 1954–1980 NA
23 Mashberg 1993 [68] USA 1972–1983 CCH M Incident in 1972–1983, US veterans No cancer or dysplasia of pharynx, larynx, lung or 
oesophagus
None
24 Perry 1993h USA about 1992 CCH M+F NS Cardiovascular diseases NS
25 Kabat 1994 [59] USA 1977–1990 CCH M+F Incident No tobacco-related diseases Age, sex, race, 
hosp, time
26 Bundgaard 1995 [105] Denmark 1986–1990 CCP M+F Histologically confirmed Population controls Age, sex, area
27 Lewin 1998 [64] Sweden 1988–1990 CCP M Incident and registered, not identified at autopsy Population controls Age, area
28 Muscat 1998 [106] USA 1977–1990 CCH M+F Incident, not mentally impaired No tobacco-related diseases Age, sex, race, time
29 Schildt 1998 [73] Sweden 1980–1989 CCP M+F Histologically confirmed, not deceased without a 
relative
Population controls Age, sex, area, vit
30 Schwartz 1998 [69] USA 1990–1995 CCP M+F Histologically confirmed squamous cell carcinoma, 
18–65 years
Population controls Age, sex
31 Boffetta 2005 [82] Norway 1966–2001 Cohort M Population sample and relatives of migrants to USA Incidence 1966–2001 NA
32 Henley 2005 [66] USA 1959–2000 Cohort M Never smokers in Cancer Prevention Study I (CPS I) 
and II (CPS II)
Mortality CPS I : 1959 to 1972 CPS II : 1982 to 2000 NA
a In studies 3 and 6 the starting year of collection of cases was not given
b CCH = case control with hospital controls, CCP = case control with population controls
c For cohort studies
d NS = not stated
e NS = not stated, NA = not applicable, rel. = religion, ins. = insurance status, hosp. = hospital, time = period of admission, occ. = occupation, type = incident or decedent, vit. = vital status
f Exposure data only available for males
g Insufficient information for females
h Attributable oral cancer risk due to smokeless tobacco use based on a case-control study at Sinai Hospital in Detroit; unpublishedB
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Table 2: Cancer sites considered in the 32 included studies
Cancer site Study numbers
1 234567891 01 11 21 31 41 51 61 71 81 92 02 12 22 32 42 52 62 72 82 93 03 13 2
B u c c a l  m u c o s a XXXX X X XX
Floor of mouth X X X X X X X X X X X
Gingiva X X
Gum/palate a X X X X XXX X X XX X
Lip X a XX X X X X X X
O r a l  c a v i t y / m o u t h X X X XX XX XXX XXXXXXX XXXX
Pharynx/alveolus X X X b X X X X XXXXX XXXX XXX XXX
Tongue a X X XX X X XX X X X
Tonsils a X XX
Salivary glands X X X X
Unspecified b XX X c XX X
a Specifically excluded by author
b Due to the joint reporting of pharynx and larynx cases, both sites were excluded from analyses
c Larynx cases could not be excluded due to incomplete reporting
Table 3: Study details and effect estimates.
Study First author, year 
of publication
Method of exposure 
assessment
Cancer site Adjustment factorsa Exposure (period) Sex Cases/
Controlsb
OR/RRc(95% CI)
1 Broders 1920 [74] NS Lip Smoking Chewing (NS) M+F 537/500 2.05 (1.48–2.83)de
None Snuff (NS) M+F 537/500 1.76 (0.12–26.2)ef
None Smokeless (NS) M+F 537/500 2.05 (1.48–2.83)efg
2 Moore 1953 [57] Interview Buccal mucosa, gum, floor of mouth None Smokeless (20+ years) M 112/38 3.00 (1.37–6.54)f
3 Wynder 1957 [58] Interview Lip, floor of mouth, gum, buccal mucosa, tongue, palate, 
tonsil, pharynx
Smokingh Chewing (ever) M 525/186 2.00 (1.16–3.47)ef
4 Peacock 1960 [93] Interview Buccal mucosa, alveolar ridge, floor of mouth Age, ins. Smokeless (20+ years) M 25/191 3.06 (1.08–8.63)di
F 20/172 2.00 (0.66–6.01)di
5 Vogler 1962 [62] Interview or questionnaire Lip, buccal mucosa, tongue, palate, gingiva, floor of mouth, 
minor salivary glandsk
None Chewing (ever) M 14/402 7.38 (4.31–12.62)dij
Snuff (ever) F 75/826 38.28 (21.49–68.15)dei
6 Vincent 1963 [94] Interview Oral cavity, pharynx None Snuff (NS) M 66/100 4.22 (1.41–12.63)fi
7 Martinez 1969 [95] Interview Mouth and pharynx Smokingl Chewing (last 20 years) M 18/81 2.29 (0.62–8.48)fim
F 16/79 0.34 (0.04–2.79)fim
8 Keller 1970 [75] Hospital records Lip Smoking Smokeless (NS) M 258/207 3.63 (1.02–12.95)d
9 Browne 1977 [96] Interview, proxy interview Buccal mucosa, upper alveolus and hard palate, lower 
alveolus, floor of mouth, pillar of fauces, soft palate, 
unspecified or multiple
None Chewing (NS) M+F 75/150 0.67 (0.27–1.66)f
10 Williams 1977 [97] Interview Lip, tongue, salivary glands, gum, mouth, pharynx None Smokeless (ever) M 190/1788 0.91 (0.53–1.56)fgi
F 79/3188 1.54 (0.37–6.42)fgi
11 Wynder 1977 [98] Interview Oral cavity None Chewing (ever) M 591/2560 1.15 (0.85–1.55)f
Snuff (ever) M 591/2560 0.62 (0.32–1.22)f
Smokeless (ever) M 591/2560 1.02 (0.78–1.34)fgn
12 Westbrook 1980 [63] Hospital records Buccal mucosa, gum None Snuff (ever) F 55/55 540.0 (60.97–4782.82)f
13 Winn 1981 [13] Interview, proxy interview Mouth and pharynx Smoking, race Snuff (ever) F 232/410 2.67 (1.83–3.90)d
14 Wynder 1983 [99] Interview Oral and pharyngeal None Chewing (ever) M 414/414 1.00 (0.62–1.61)ef
Snuff (ever) M 414/414 0.42 (0.11–1.65)fB
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Smokeless (ever) M 414/414 0.90 (0.57–1.41)efgn
15 Stockwell 1986 [65] Medical records Lip, tongue, salivary glands, gum, floor of mouth, other 
parts of mouth, pharynx
None Smokeless (ever) M+F 1462/8285 2.02 (1.01–4.02)fi
16 Blot 1988 [100] Interview, proxy interview Oral and pharyngeal None Smokeless (ever) M 762/837 0.85 (0.57–1.26)ef
F 352/431 3.44 (1.09–10.91)ef
17 Spitz 1988 [101] Questionnaire Larynx, tongue, orohypopharynx, oral cavityo None Chewing (ever) M+F 185/185 1.00 (0.54–1.85)f
NS Snuff (ever) M+F 185/185 3.40 (1.00–10.90)p
None Smokeless (ever) M+F 185/185 1.05 (0.57–1.91)fg
18 Franco 1989 [102] Interview Oral cavity, tongue, gum, floor of mouth None Smokeless (ever) M+F 232/464 1.40 (0.59–3.33)f
19 Blomqvist 1991 [103] Questionnaire Lower lip Smokingl Snuff (ever) M+F 14/10 0.67 (0.08–5.75)f
20 Maden 1992 [104] Interview Lip, tongue, gum, floor of mouth, oropharynx, other parts 
of mouth
Age Smokeless (ever) M 131/136 4.50 (1.50–14.30)p
21 Sterling 1992 [67] Interview (controls), proxy 
interview (cases)
Oral and pharyngeal Smoking, sex, race, age, alc, 
occ.
Smokeless (100+ times) M+F 6976/NS 1.04 (0.41–2.68)q
Sex, race, age Snuff (ever) M+F 6976/NS 2.42 (1.28–4.59)p
22 Zahm 1992 [72] Questionnaire Buccal cavity, pharynx Age, time Smokeless (ever) M 129/248046 4.11 (2.90–5.84)r
23 Mashberg 1993 [68] Interview Oral cavity, oropharynx Smoking, age, race, alc. Snuff (ever) M 359/2280 0.80 (0.40–1.90)p
Chewing (ever) M 359/2280 1.00 (0.70–1.40)p
Smokeless (ever) M 359/2280 0.96 (0.70–1.33)nq
24 Perry 1993s NS Oral Smoking, age, sex, race, alc, 
occ.
Smokeless (100+ times) M+F 133/678 1.43 (0.64–3.21)q
25 Kabat 1994 [59] Interview Tongue, floor of mouth, gums, gingiva, buccal mucosa, 
palate, retromolar area, tonsil and other pharynx
Smokingl Snuff (ever) M+F 195/918 4.79 (1.19–19.30)f
Smoking Chewing (ever) M 1097/2075 1.11 (0.81–1.53)de
26 Bundgaard 1995 [105] Questionnaire Retromolar area, buccal mucosa, floor of mouth, hard 
palate, upper alveolus, lower alveolus, tongue
None Chewing (ever) M+F 161/400 1.44 (0.59–3.51)d
27 Lewin 1998 [64] Interview Oral and pharyngeal Smoking, age, area, alc. Snuff (ever) M 266/641 0.98 (0.63–1.50)r
28 Muscat 1998 [106] Interview Major salivary gland None Chewing (ever) M+F 128/114 0.89 (0.18–4.49)d
Smokeless (ever) M+F 128/114 1.19 (0.26–5.45)dgn
29 Schildt 1998 [73] Questionnaire from next-of-kin 
for deceased cases/controls
Lip, tongue, gum, mouth Smoking, alc. Snuff (ever) M+F 354/354 0.80 (0.50–1.30)p
None Chewing (ever) M+F 354/354 0.60 (0.20–2.00)p
Smokeless (ever) M+F 354/354 0.87 (0.61–1.25)fgn
30 Schwartz 1998 [69] Interview Tongue, gum, floor of mouth, tonsils, oropharynx, other 
parts of mouth
Smoking, age, alc, sex Smokeless (ever) M 165/302 1.00 (0.40–2.30)p
31 Boffetta 2005 [82] Questionnaire Oral and pharyngeal Smoking, age Snuff (ever) M 34/10136 1.10 (0.50–2.41)p
32 Henley 2005 [66] Questionnaire Oral and pharyngeal Smokingl, age, race, educ., 
alc, exer, asp, bmi, diet, occt.
Smokeless (current) M (CPS-
I)
13/77407 2.02 (0.53–7.74)p
Smokeless (ever) M (CPS-
II)
46/114809 0.90 (0.12–6.71)p
a alc = alcohol consumption, asp = aspirin, bmi = body mass index, educ = education, exer = exercise, ins = insurance status, occ = occupation
b At risk population for cohort studies
c OR = odds ratio (case-control studies), RR = relative risk (cohort studies)
d Estimated from multiple independent 2 × 2 tables using fixed-effect meta-analysis
e Numbers of exposed and unexposed cases and controls estimated from proportions exposed given numerically
f Estimated from 2 × 2 table
g Numbers of exposed cases and controls combined over levels of exposure
h Analysis based on smokers only (only one SLT user was a non-smoker)
i Numbers of cases combined over cancer types specified
j Numbers of exposed and unexposed cases and controls estimated from proportions exposed given graphically
k Due to the joint reporting of pharynx and larynx cases, both sites excluded from analysis
l Analysis based on non-smokers only
m Note that in Table 13 of source chewing only data for mouth cancer wrongly given under pipe only
n Calculated assuming no-one chewed tobacco and used snuff
o Larynx cases cannot be sorted out due to incomplete reporting
p As reported by the authors
q Estimated from non-independent relative risks by level of exposure using method of Fry and Lee
r Estimated from non-independent relative risks for cancer types using method of Fry and Lee
s Attributable oral cancer risk due to smokeless tobacco use based on a case-control study at Sinai Hospital in Detroit; unpublished
t Occupation only adjusted for in CPS-II
Table 3: Study details and effect estimates. (Continued)BMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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studies contrasted never and ever use of smokeless
tobacco and did not specify any minimal duration of use,
but three studies (2, 4, 7) considered only exposures of 20
years or more. Separate estimates by gender were only
available in five studies (4, 7, 10, 16, 25). Estimates were
only available for chewing tobacco in four studies (3, 7, 9,
26), for snuff in six studies (6, 12, 13, 19, 27, 31) and for
unspecified smokeless tobacco use in 12 studies (2, 4, 8,
10, 15, 16, 18, 20, 22, 24, 30, 32). Estimates were availa-
ble for more than one type of product in the remaining 10
studies (1, 5, 11, 14, 17, 21, 23, 25, 28, 29), all but two (5,
25) including an estimate for overall smokeless tobacco
use. Most of the estimates were for smokers and non-
smokers combined. Exceptionally, that for chewing
tobacco, in study 3, was for smokers, those for chewing
tobacco in study 7 were for nonsmokers, those for snuff in
studies 19 and 25 were for nonsmokers, and those for
smokeless tobacco in study 32 were for nonsmokers. Two
effect estimates based on different data sets (the cancer
prevention studies CPS-I and CPS-II) were provided by
study 32.
Overall, Table 3 contains 53 effect estimates, of which 11
were provided by the authors and 42 were calculated from
data presented. Superscript notes attached to the estimates
give some detail on how the calculations were carried out.
Non-independent estimates were combined over level of
exposure in two studies (21, 24), over type of smokeless
product in one study (23) and over cancer types in two
studies (22, 27). In five studies (11, 14, 23, 28, 29) com-
bined estimates for smokeless tobacco use were calculated
approximately assuming that noone chewed tobacco and
used snuff.
As described in Table 3, exposure data were collected
directly from patients/controls by interview in 15 studies
(2, 3, 4, 6, 7, 10, 11, 14, 18, 20, 23, 25, 27, 28, 30), by
questionnaire in six (17, 19, 22, 26, 31, 32), and by both
in one (5). In five studies (9, 13, 16, 21, 29), both direct
and proxy interviews were conducted. In four of these, the
proportion of proxy interviews was much higher in cases
than in controls, and only in study 29, where controls
were matched with cases on vital status, was the propor-
tion the same. Three studies (8, 12, 15) used medical
records for exposure assessment. For study 12 this may
have led to the probability of reporting smokeless tobacco
use being much higher in cases than in controls [10,11].
Two studies (1, 24) did not clearly describe the source of
exposure assessment.
Overall 16,540 cases of oral cancer were used in the
present analysis. Of these, 222 were in three cohort stud-
ies (22, 31, 32), 5,580 were in 19 case-control studies with
hospital controls (1–6, 8, 10–14, 17–19, 23–25, 28),
10,704 were in nine case-control studies with population
controls (9, 15, 16, 20, 21, 26, 27, 29, 30), and 34 were in
the one case-control study with both types of control
(study 7). The first, second and third quartiles of the
number of cases considered were 94, 200, and 387. The
smallest study had 14 cases (study 19) and the largest
6,976 (study 21, based on a sample of US death certifi-
cates of 1986). Excluding study 21, where numbers of
controls were not available, a total of 29,009 controls
were considered in the 28 case-control studies, of which
17,313 were hospital, 11,536 population and 160 mixed.
Diagnoses of oral cancer were reported as histologically
confirmed in 19 studies (3, 4, 7, 8, 11, 12, 14, 16, 17, 18,
20, 23, 25, 26, 27, 28, 29, 30, 31) and as confirmed for
some of the cases by four studies (9, 10, 15, 24). Histolog-
ical confirmation was not reported by six studies (1, 2, 5,
6, 13, 19), and death certificates (presumably without
100% histological verification) were used in three studies
(21, 22, 32).
Figure 1 presents the 38 study-specific risk estimates and
their 95% CI for all types of smokeless tobacco. Studies
conducted before about 1965 uniformly show effect esti-
mates above one, with studies published in the last 10
years or so showing no statistically significant increases.
Figures 2 to 4 similarly present, respectively, the estimates
for chewing tobacco, snuff and unspecified smokeless
tobacco use. Here the estimates are separated according to
whether they were unadjusted or adjusted for smoking.
The precision of estimates for chewing tobacco is in gen-
eral higher than the precision for snuff or unspecified
smokeless tobacco use. The relatively low precision of esti-
mates for unspecified smokeless tobacco may reflect the
variety of exposures investigated. For snuff the smoking
adjusted relative risks seem lower than the unadjusted rel-
ative risks, but the difference is less marked for chewing
tobacco and unspecified smokeless tobacco use. The fig-
ures also include results of random-effects meta-analyses,
which are discussed in the next section.
Meta-analysis
Table 4 summarizes the results of the meta-analyses. Sep-
arate results are shown based on 14 estimates specifically
for chewing tobacco, 15 specifically for snuff, 24 for
smokeless tobacco, and 38 for "all" types of smokeless
tobacco. Random-effects estimates appear in Table 4 only
where heterogeneity was detected.
Based on the 38 estimates for all types of smokeless
tobacco shown in Figure 1, the fixed-effect estimate,
regardless of adjustment for potential confounding varia-
bles, is 1.54. This is similar to the fixed-effect estimate of
1.58 based on studies without any adjustment. In both
cases, heterogeneity is observed, substantial enough to BMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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Forest plot of study-specific effect estimates and 95% CIs for chewing tobacco Figure 2
Forest plot of study-specific effect estimates and 95% CIs for chewing tobacco.
Forest plot of study-specific effect estimates and 95% CIs for all types of smokeless tobacco use Figure 1
Forest plot of study-specific effect estimates and 95% CIs for all types of smokeless tobacco use.BMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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Forest plot of study-specific effect estimates and 95% CIs for overall smokeless tobacco use Figure 4
Forest plot of study-specific effect estimates and 95% CIs for overall smokeless tobacco use.
Forest plot of study-specific effect estimates and 95% CIs for snuff Figure 3
Forest plot of study-specific effect estimates and 95% CIs for snuff.BMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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cast some doubts on the corresponding random-effects
estimates.
When only those estimates adjusted for smoking are con-
sidered, the heterogeneity is markedly reduced, and the
fixed-effect estimate also reduces, to 1.31. Since signifi-
cant heterogeneity remains, the random-effects estimate
of 1.35 is the preferred overall estimate. When the analysis
is further restricted to estimates adjusted for both smoking
and alcohol consumption, no heterogeneity is seen.
Moreover, the point estimate is close to unity (1.02; 95%
CI 0.82–1.28). The lack of detectable risk when these fac-
tors are accounted for seems consistent with an important
confounding effect of smoking and alcohol, both well
known major risk factors for oral cancer. For example,
Döbróssy [61] reports that smoking and alcohol con-
sumption each "may account for a two- to three-fold
increase in risk" and "when tobacco smoking and alcohol
consumption are combined, they may increase the risk by
more than 15-fold."
The same pattern of estimates decreasing after adjustment
for smoking and alcohol can be seen from the separate
results for chewing tobacco, snuff and unspecific smoke-
less tobacco, although for snuff and particularly chewing
tobacco numbers of estimates adjusted for both factors are
very low. None of the analyses show any significant
increase in risk following adjustment for both factors.
The elevated random-effects estimate 5.15 for snuff based
on unadjusted data (see also Figure 3) is mainly due to
two studies with evident weaknesses [62,63]. The study by
Vogler et al. [62] did not match controls to cases and the
effect estimate of 38.28 (21.49–68.15) was computed
based on rather incompletely reported information. With
regard to the study by Westbrook et al. [63], both
IARC[10] and the US Surgeon General [11] pointed out
that the risk estimate of 540.0 (60.97–4782.82) is very
unreliable, exposure assessment being based on hospital
records, where documentation of smokeless tobacco use
is much more likely in cases than in controls. Omitting
these two studies, the unadjusted random-effects estimate
Table 4: Meta-analyses of the risk of oral cancer in smokeless tobacco users compared to non-users (based on the estimates given in 
Table 3).
Heterogeneity
Type of 
smokeless 
tobacco
No. of 
estimates 
combined
Adjustment 
factorsa
Fixed-effect 
OR/RR (95%CI)
Random-effects 
OR/RR (95%CI)
χ2 I2 p(χ2)
Allb 38 any 1.54 (1.40–1.69) 1.87 (1.40–2.48) 283.3 86.9 < 0.0001
19 none 1.58 (1.39–1.78) 2.18 (1.35–3.53) 232.1 92.2 < 0.0001
15 sm 1.31 (1.13–1.53) 1.35 (1.04–1.76) 28.7 51.3 0.0114
7 sm, al 1.02 (0.82–1.28) 1.9 0.0 0.9321
7 sm, al, age 1.02 (0.82–1.28) 1.9 0.0 0.9321
Chewing 14 any 1.38 (1.21–1.58) 1.36 (0.98–1.89) 61.2 78.8 < 0.0001
8 none 1.37 (1.13–1.68) 1.28 (0.71–2.30) 46.4 84.9 < 0.0001
6 sm 1.39 (1.16–1.66) 1.42 (0.99–2.03) 14.9 66.3 0.0110
1 sm, al, age 1.00 (0.71–1.41) -- -- --
Snuff 15 any 2.00 (1.67–2.39) 2.39 (1.17–4.89) 182.4 92.3 < 0.0001
7 none 5.36 (3.73–7.69) 5.15 (0.88–30.2) 116.7 94.9 < 0.0001
7 sm 1.35 (1.09–1.69) 1.28 (0.76–2.14) 24.8 75.8 0.0004
3 sm, al 0.88 (0.65–1.18) 0.4 0.0 0.7998
2 sm, al, age 0.93 (0.64–1.36) 0.2 0.0 0.6555
Smokelessc 24 any 1.27 (1.13–1.42) 1.46 (1.17–1.83) 65.6 65.0 < 0.0001
13 none 1.18 (1.03–1.35) 1.26 (0.98–1.61) 31.5 61.9 0.0017
7 sm 1.09 (0.85–1.42) 5.4 0.0 0.4967
6 sm, al, age 1.04 (0.80–1.35) 1.8 0.0 0.8751
4 sm, al, age, ss 1.32 (0.77–2.25) 0.8 0.0 0.8467
a Smoking (sm), alcohol (al), age, social status (ss)
b For each study/sex, the OR/RR for smokeless tobacco from Table 3 was included if available, otherwise that for chewing tobacco or snuff was 
used. For study 25 where estimates for snuff and chewing tobacco, but not smokeless tobacco, were available, that for chewing tobacco was 
included as it was for smokers and nonsmokers combined
c This includes all the OR/RR estimates from Table 3 where the exposure was smokeless, both from studies where only estimates for unspecified 
exposure were available and from studies where it had been estimated from the separate data for chewing tobacco and snuffBMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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for snuff falls to 1.40 (0.51–3.86), with the I2  value
reduced from 94.9 to 71.6.
Sensitivity analyses
Of the 38 estimates included in the all smokeless tobacco
analyses, six (from studies 3, 7, 19 and 32) were for smok-
ers or for nonsmokers. Eliminating these estimates so that
all the data were for smokers and nonsmokers combined
reduced the fixed-effect estimate only slightly, from 1.54
(1.40–1.69) to 1.53 (1.39–1.68) but increased the ran-
dom-effects estimate from 1.87 (1.40–2.48) to 1.94
(1.43–2.65).
Of the 38 estimates, five (from studies 11, 14, 23, 28 and
29) were derived approximately assuming that there were
no joint users of chewing tobacco and snuff. Replacing
these by estimates for chewing tobacco in US studies and
for snuff in Swedish studies increased the fixed-effect esti-
mate to 1.62 (1.47–1.78) but left the random-effects esti-
mate the same at 1.87 (1.40–2.50).
Heterogeneity
Of the 38 estimates used in the all smokeless tobacco
analyses, only five were provided directly in the publica-
tions, the remaining 33 being derived from the data avail-
able. Although fixed-effect estimates were lower for the
published data (1.21; 0.78–1.89) than for the derived
data (1.55; 1.41–1.71), the difference was not statistically
significant (χ2 = 1.15, p = 0.28). Although the number of
published estimates is too few for reliable interpretation,
this suggests that no bias to the null has been introduced
by considering derived estimates.
A more detailed heterogeneity analysis was also under-
taken (Table 5). Since the number of estimates for specific
types of smokeless tobacco (14 for chewing tobacco and
15 for snuff) was rather small, and subdivision for possi-
ble sources of heterogeneity would have resulted in vari-
ous cells containing at most a single study, this analysis
was conducted using the estimates included in the all
smokeless tobacco analyses. Since there were few esti-
mates that were adjusted for both smoking and alcohol
consumption, and few adjusted estimates which did not
include smoking as one of the factors adjusted for, the het-
erogeneity analyses were conducted based firstly on the 19
estimates that were unadjusted for any factor and second
on the 15 estimates that were adjusted for smoking,
regardless of any other adjustment. This left a reasonable
number of individual estimates in each of the two sets to
investigate the possible role of type of smokeless tobacco,
sex, study design, study location and study period on the
estimated effect.
Since the potential sources of heterogeneity must be con-
sidered as competing, and because of possible residual
confounding, for example due to alcohol consumption,
the analyses probably overestimate the true contributions
to heterogeneity of the individual factors assessed. True
proportions of explained heterogeneity could only be esti-
mated from multifactorial analyses of primary data.
By far the most profound source of heterogeneity was
study period. In smoking-adjusted estimates, 81.4 percent
of the total heterogeneity was accounted for by between-
period heterogeneity. Studies conducted before 1980
showed an excess risk, while no increase was seen from
studies conducted in 1980 or later. In smoking-unad-
justed estimates, period also accounted for a large propor-
tion (46.9%) of the total heterogeneity.
Although 67.7% of the total heterogeneity could be
accounted for by type of tobacco in the unadjusted analy-
ses, the corresponding proportion for the smoking-
adjusted risk estimates was only 15.1%. Although the
smoking-adjusted effect estimates for chewing tobacco
(1.29) and snuff (1.62) were elevated, this may reflect
uncontrolled confounding by alcohol as no increase was
seen in the analyses in Table 4 based on estimates
adjusted for smoking and alcohol.
Studies conducted in the US indicated an increased risk of
oral cancer in both unadjusted data (by 76%) and
adjusted data (by 39%). Though no significant effect was
seen in Scandinavia or in other countries, numbers of esti-
mates were relatively few (2 in Scandinavia, 1 in UK and
1 in Brazil for the unadjusted data; 3 in Scandinavia, 2 in
Puerto Rico for the adjusted data), and heterogeneity by
location was only demonstrated for the unadjusted data.
Sex-specific overall risk estimates were higher for women
than men. The fact that the sex difference was larger using
unadjusted estimates suggests that at least part of it may
be due to confounding.
Hospital-based case-control studies provided higher risk
estimates than those from other study designs, and their
estimates were much more heterogeneous. The reason for
this is unclear.
Figure 5 plots all study-specific effect estimates on a loga-
rithmic scale against their precision. There is only a slight
inverse association between precision and variability of
individual estimates around the overall random-effects
estimate of 1.87 (dotted vertical line). The observed asym-
metry of the funnel plot suggests that publication bias
cannot be excluded.
Never smokers
While the previous analyses are based on results, where
available, for the whole population studied, includingBMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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Table 5: Heterogeneity of the oral cancer smokeless tobacco relative risk, unadjusted and adjusted for cigarette smoking (based on 
the estimates given in Table 3).
Unadjusted for any factor Adjusted for smoking
Heterogeneityb Heterogeneityb
Factor N OR/RR 
(95%CI)a
χ2 I2 p(χ2)c N OR/RR 
(95%CI)a
χ2 I2 p(χ2)c
All estimatesd 19 1.58 
(1.39–1.78)
232.1 92.2 < 0.0001 15 1.31 
(1.13–1.53)
28.7 51.3 0.0114
Type
Chewing tobacco 33 . 2 0  
(2.12–4.82)
23.8 91.6 < 0.0001 4 1.29 
(0.99–1.69)
5.6 46.2 0.1342
Snuff 3 27.9 
(17.0–45.9)
19.6 89.8 0.0001 4 1.62 
(1.24–2.11)
13.4 77.7 0.0038
Smokelesse 13 1.18 
(1.03–1.35)
31.5 61.9 0.0017 7 1.09 
(0.85–1.42)
5.4 0.0 0.4967
Between levels 157.3 67.7 < 0.0001 4.3 15.1 0.1142
Sex
Female 4 20.3 
(12.6–32.5)
35.0 91.4 < 0.0001 2 2.51 
(1.73–3.64)
3.5 71.5 0.0610
Male 71 . 2 7  
(1.07–1.51)
60.6 90.1 < 0.0001 10 1.15 
(0.97–1.37)
10.8 16.4 0.2925
Both 81 . 3 5  
(1.11–1.64)
16.5 57.5 0.0213 3 1.19 
(0.66–2.15)
0.6 0.0 0.7573
Between levels 120.1 51.7 < 0.0001 13.9 48.4 0.0010
Study design
Case-control, hospital controls 13 1.90 
(1.64–2.21)
200.4 94.0 < 0.0001 7 1.41 
(1.18–1.68)
22.0 73.7 0.0009
Case-control, population
controls
61 . 0 1  
(0.81–1.27)
11.0 54.6 0.0514 3 0.99 
(0.69–1.42)
0.0 0.0 0.9935
Case-control, mixed controls 0- - - - - - - - 2 f 1.35 
(0.44–4.13)
-- -- 0.1337
Cohort 0 -- -- -- -- 3 1.24 
(0.65–2.36)
-- -- 0.7062
Between levels 20.7 8.9 < 0.0001 3.0 10.4 0.3928
Study location
USA 15 1.76 
(1.54–2.02)
215.6 93.5 < 0.0001 10 1.39 
(1.17–1.64)
23.7 62.1 0.0047
Scandinavia 20 . 9 3  
(0.67–1.30)
1.1 5.3 0.3041 3 0.99 
(0.68–1.45)
0.2 0.0 0.9054
Other 2g 0.99 
(0.53–1.84)
1.3 24.6 0.2495 2h 1.35 
(0.44–4.13)
2.2 55.5 0.1337
Between levels 14.2 6.1 0.0008 2.5 8.8 0.2810
Study period
-1969 54 . 4 9  
(3.55–5.66)
79.8 95.0 < 0.0001 4 2.02 
(1.28–3.20)
3.6 15.8 0.3129
1970–1979 51 . 0 5  
(0.84–1.33)
33.0 87.9 < 0.0001 1 2.67 
(1.83–3.90)
0.0 0.0 --
1980–1989 71 . 0 1  
(0.83–1.23)
10.4 42.4 0.1080 2 0.97 
(0.71–1.31)
0.0 0.0 0.8743
1990+ 21 . 3 7  
(0.64–2.96)
0.0 0.0 0.8321 8 1.10 
(0.88–1.37)
1.8 0.0 0.9719
Between levels 108.9 46.9 < 0.0001 23.4 81.4 < 0.0001
a Fixed-effect estimates
b For the "Between levels" rows, the I2 column contains the percentage of variation explained by the factor levels rather than the heterogeneity I2 
statistic
c The probability for the heterogeneity χ2 between studies within levels is shown, except that for the "Between levels" rows, the probability is for the 
between levels χ2
d For each study/sex, the OR/RR for smokeless tobacco from Table 3 was included if available, otherwise that for chewing tobacco or snuff was used. 
For study 25 where estimates for snuff and chewing tobacco, but not smokeless tobacco, were available, that for chewing tobacco was included as it was 
for smokers and nonsmokers combined
e This includes all the OR/RR estimates from Table 3 where the exposure was smokeless, both from studies where only estimates for unspecified 
exposure were available and from studies where it had been estimated from the separate data for chewing tobacco and snuff
f In study 7 (two estimates), both hospital and population controls were used
g Studies 9 (UK) and 18 (Brazil)
h Study 7 (conducted in Puerto Rico, two estimates)
I Since only one study with an effect estimate adjusted for smoking was conducted between 1970 and 1979 (study 13), an additional assessment of 
heterogeneity was carried out based on two periods (-1979 vs. 1980+). The corresponding overall effect estimates, based on 5 and 10 studies 
respectively, were 2.39 (1.78–3.19) and 1.05 (0.88–1.26), with p < 0.0001 for between levels heterogeneityBMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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smokers and never smokers, six studies provided oral can-
cer relative risks specifically among never smokers. The
estimates, two for snuff use and four for general smokeless
tobacco use, are summarized in Table 6, as are meta-anal-
ysis results. Numbers of exposed cases are extremely low,
only 44 in total, and six or less for all but one of the esti-
mates. Although the data are somewhat suggestive of an
association, neither the fixed-effect estimate of 1.30
(95%CI 0.82–1.93) nor the random-effects estimate of
1.94 (0.88–4.28) is statistically significant and the data
are heterogeneous (I2 = 63.1). Also shown in Table 6 is an
additional age- and region-adjusted estimate of 4.70
(1.60–13.80) for ever snuff use in males. This estimate is
for oral, larynx and oesophagus cancer combined, so does
not satisfy our original inclusion criteria. Were it included,
the random-effects estimate would become significant, at
2.20 (1.04–4.67).
Discussion
This report is based on data relating oral cancer risk to the
consumption of chewing tobacco and snuff as used in
Western countries. Our main analyses, based on results
for smokers and nonsmokers combined where possible,
considers 53 individual effect estimates based on 32 stud-
ies published from 1920 to 2005. This represents 11 more
studies than considered in the previous most recent quan-
titative review of the evidence[16]. 16,540 cases of oral
cancer were included in studies of different design, size,
and quality. Many of the 32 reports have limitations and
present less information than is ideal for a meta-analysis.
Shortcomings include small numbers of cases (particu-
larly exposed cases), lack of histological confirmation,
lack of division by cancer site, as well as an unclear
description of inclusion and exclusion criteria, details of
case and control selection, and methods of exposure
assessment. Furthermore, exposure details such as type of
smokeless tobacco, duration and frequency of use were
often not considered. At the analysis level the main weak-
nesses were failure to adjust results for important poten-
tial confounders and to present results separately for
major subgroups, particularly by sex, smoking and alco-
hol. These weaknesses inevitably limit the inferences that
can be drawn. Nevertheless some conclusions can be
drawn from the present results.
Apart from the diversity of designs, samples, procedures,
methods, and types of smokeless tobacco investigated, the
individual effect estimates were themselves highly varia-
ble, particularly for snuff, where the I2 statistic for the 15
estimates was 94.9 (see also Figure 1). Given the well-
known strong relationships of smoking and alcohol con-
sumption to oral cancer risk [52], and given that 33 of the
53 estimates were unadjusted for either smoking or alco-
hol, it was perhaps unsurprising that this heterogeneity
was highly reduced, and indeed essentially eliminated (I2
= 0 for each of the types of smokeless tobacco) by restrict-
ing attention to estimates adjusted for these two variables.
Not only did such adjustment remove the substantial het-
erogeneity, but it removed the association, with an overall
estimate for all smokeless tobacco use of 1.87 (1.40–2.48)
Funnel plot of 38 study-specific effect estimates against precision (1/variance of log effect estimate) Figure 5
Funnel plot of 38 study-specific effect estimates against precision (1/variance of log effect estimate).BMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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reducing to 1.02 (0.82–1.28). The latter estimate is con-
sistent with risk of oral cancer being independent of
smokeless tobacco use, though a small increase cannot of
course be totally excluded.
The lower effect estimates seen in studies that adjust for
alcohol and smoking need not wholly be due to the
adjustment. For example, unadjusted estimates may
derive from studies which are methodologically weaker,
perhaps because smokeless tobacco was not a central
issue. As such it is important to look at other information
which may cast light on the role of confounding by alco-
hol or smoking. One way of attempting to eliminate
potential confounding effects of smoking is to restrict
attention to study of the effects of smokeless tobacco use
in never smokers. Unfortunately only six studies provided
effect estimates for oral cancer or data from which these
could be calculated. Although the data are suggestive of an
association, the meta-analysis estimates (see Table 6) are
inconclusive and the data are heterogeneous. They are
also no doubt open to publication bias, since many
researchers would not present null results based on very
limited data. These data involve very few exposed cases.
Any data available for subjects who have never smoked
and never used alcohol would be even sparser. As can be
seen from Table 6, one additional study [64] provided
results that were not for oral cancer specifically, but
included other forms of head and neck cancer. Inclusion
of these results do not affect the above conclusions.
Another study [65] also seemed at first glance to provide
possibly relevant results, with significant increases noted
for some oral sites and not others. However this study
only asked about the primary type of tobacco used, com-
paring smokeless tobacco users, who may well also have
smoked, with subjects who never used any tobacco prod-
uct at all. These results are clearly not restricted to never
smokers and are open to confounding.
To further assess possible effects of adjustment, it is help-
ful to consider in more detail those studies which provide
Table 6: Effect estimates for never smokersa
Study First author, year of 
publication
Adjustment factors Exposure Sex Exposed cases OR/RR (95%CI)
Studies providing result specific for oral cancer
8 Keller 1970 [75] None Smokeless M 4 3.04 (0.62–14.99)
16 Blot 1988 [100] Age, race, location, 
respondent
Smokeless F 6 6.20 (1.90–19.80)
19 Blomqvist 1991 [103] None Snuff M+F 2 0.67 (0.08–5.75)
25 Kabat 1994 [59] None Smokeless M 4 1.59 (0.51–4.96) 
F 4 38.7 (2.1–723.6)b
29 Schildt 1998 [73] Age, sex, residence Snuff M+F 19 0.70 (0.40–1.20)
32 Henley 2005 [66] Age, race, education, 
alcohol, exercise, aspirin, 
body mass index, diet, 
occupationc
Smokeless M (CPS-I) 4 2.02 (0.53–7.74)
M (CPS-II) 1 0.90 (0.12–6.71)
Fixed-effect meta-analysis estimate for six studies 1.30 (0.87–1.93)
Random-effects meta-analysis estimate for six studies 1.94 (0.88–4.28)
Heterogeneity χ2 (df) 18.99 (7)
p 0.0082
I2 63.13
Additional study providing result for oral, larynx and oesophagus cancer combined
27 Lewin 1998 [64] Age, region Snuff M 9 4.70 (1.60–13.80)
Fixed-effect meta-analysis estimate for all seven studies 1.51 (1.04–2.19)
Random-effect meta-analysis estimate for all seven studies 2.20 (1.04–4.67)
Heterogeneity χ2 (df) 23.82 (8)
p 0.0025
I2 66.42
aSee the discussion section for the reasons why data from study 15 [65] were not included in Table 6
b There were no exposed controls and the OR was estimated by adding 0.5 to each cell in the 2 × 2 table
cOccupation only adjusted for in CPS-IIBMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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both adjusted and unadjusted estimates. Lewin et al. [64]
saw no effect of snuff before or after adjustment for alco-
hol and smoking, but did observe a clear dose-response
relationship both with alcohol and smoking. Henley et al.
[66] found that the non-significant association of oral
cancer with smokeless tobacco use seen in never smokers
was further reduced after adjustment for alcohol con-
sumption. Perry et al. (Attributable oral cancer risk due to
smokeless tobacco use based on a case-control study at
Sinai Hospital in Detroit; unpublished) found that addi-
tional adjustment for alcohol and smoking reduced risk
estimates adjusted only for sex, race, and age from 2.51 to
1.86 and from 1.30 to 0.93 in groups with, respectively
lower and higher smokeless tobacco use. Sterling et al.
[67] found that a significant sex, race, and age-adjusted
association (2.42) in ever as compared to never smokeless
tobacco users was virtually eliminated after additional
adjustment for alcohol consumption, smoking and occu-
pation. These authors emphasized the strong dose-
response for alcohol consumption (as seen also in other
studies considered [68,69]) as compared to the lack of
association for smokeless tobacco use. Although the evi-
dence is limited, the findings are consistent with the
notion that confounding by smoking and particularly by
alcohol consumption, clearly shown to be a major risk
factor in oral cancer [70], is an important consideration.
Unfortunately, the number of estimates adjusted for both
smoking and alcohol consumption was rather limited.
Overall estimates of the risks associated with chewing
tobacco and snuff which can reasonably be compared
with each other could therefore be based only on those
study-specific estimates (six and seven, respectively)
which were adjusted at least for smoking. However, the
corresponding estimates of 1.42 (0.99–2.03) and 1.28
(0.76–2.14) have quite low precision and provide little
useful information on whether the associations truly dif-
fer. Anyway, they are likely to be biased upward by uncon-
trolled confounding by alcohol.
For confounding to occur it is necessary for smokeless
tobacco users and non-users to differ in their smoking and
alcohol consumption. However relevant data seem quite
limited and somewhat variable. The evidence seems more
consistent for smoking where data indicating a positive
relationship with smokeless tobacco use are seen in pub-
lished studies in the USA [59,71,72] and in Sweden [73]
and also in unpublished data provided by Statistics, Swe-
den (I Sjöberg, personal communication). For alcohol
consumption, one study in Sweden [73] and one in the
US [43] report a strong association, consistent with the
possibility of substantial confounding, but such an asso-
ciation is not clearly evident in other studies. Thus data for
men in CPS I and CPS II [66] and from the first National
Health and Nutrition Examination Survey [NHANES
I][41,71] show only a weak association, and, in women,
reported alcohol consumption in NHANES I is clearly
lower in smokeless tobacco users than in non-smokeless
tobacco users, both in smokers and nonsmokers. In a
study in North Carolina Winn et al. [13] reported that
"most women who dipped snuff did not smoke cigarettes
or consume alcoholic beverages," though Nilsson [14]
suggested that alcohol consumption may not have been
considered proper behaviour for women when the study
was conducted, and that this may have led to it being sub-
stantially underreported. Whether smokeless tobacco
users are more likely to underreport alcohol consumption
is unclear.
The importance of confounding by alcohol consumption
cannot, however, be fully resolved from the data availa-
ble. Not only are the available data on the association of
alcohol and smokeless tobacco very limited, they are
unadjusted for age and race and usually for smoking or
sex. Anyway the association may vary by type of smokeless
tobacco, type of alcohol, country and period. It certainly
seems to us that, at least in some studies, observed differ-
ences in risk of oral cancer associated with use of smoke-
less tobacco and type of tobacco used may be due to
confounding by alcohol. In this context it should be noted
that other potential sources of confounding are not even
mentioned by most authors, like exposure to sunlight
(being relevant for lip cancer) which might (as might the
use of smokeless tobacco) show a social gradient due to
an association with the type of occupation.
Although conclusions based on adjusted estimates seem
more convincing than those based on unadjusted ones,
they are still not very reliable. One reason is the small
number of available estimates. A second reason is the lim-
ited nature of the adjustment – thus many of the studies
that adjusted for smoking did not take into account
amount smoked (e.g. [13,74,75]) and one of those that
did [68] combined never and light smokers into a single
category. Simple adjustment for smoking in broad groups,
e.g. never/former/current, may bias risk estimates for
smokeless tobacco downwards if in fact smokers who also
use smokeless tobacco smoke fewer cigarettes than smok-
ers who do not. The evidence here seems somewhat con-
flicting, with some studies [73,76] reporting similar
cigarette consumption in the two groups, two studies
[77,78] reporting somewhat lower consumption in the
smokers who also use smokeless tobacco, and one study
[41] reporting somewhat higher consumption (here
measured by pack-years). Though it would clearly have
been better had all studies adjusted for daily cigarette con-
sumption, any bias from this source is likely to be modest.
Adjusting for whether or not the subject is a smoker seems
to be of more importance.BMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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A third reason for unreliability of the adjusted estimates is
the variability of the findings. As the heterogeneity analy-
sis revealed, study period was a major source, with smaller
risks found in more recent studies. In fact, those studies
which reported very large relative risk estimates for spe-
cific sites [13,62,63] are rather old. Despite methodologi-
cal limitations, the strength of these site-specific effects
indicates that use of oral snuff in the USA at that time was
associated with an increased oral cancer risk, especially at
locations where the snuff was held. The secular decline in
relative risk is encouraging and suggests that even if cur-
rent use of Western smokeless tobacco poses some risk, it
is substantially less than it was decades ago. This decline,
and also the decline in US oral cancer rates, may relate to
the fact that levels of tobacco-specific nitrosamines
[TSNAs] in American smokeless tobacco products, histor-
ically much higher than in their Swedish counterparts,
have declined by more than 70 percent in the last 25 years
[52,79]. However we note that there is no definitive evi-
dence linking TSNAs in smokeless tobacco products with
oral cancer risk, and that the available data are insufficient
to take into account reliably the time lag between smoke-
less tobacco use and possible development of oral cancer.
Our analyses of smoking adjusted risks seemed to suggest
that, compared to non-users, female users of smokeless
tobacco might be at higher risk than male users, with
fixed-effect relative risks of 2.51 vs 1.15. The result for
females is, however, based on only two studies, of which
only the Winn et al. study [13] found an excess risk. Ran-
dom-effects estimates are similar for women (1.25) and
men (1.19), and though one cannot rule out the possibil-
ity of an increased effect in women, one cannot infer this
from the limited data.
Our analyses showed some indications of publication
bias, a finding supported by others [80]. Specific indices
of publication bias can also be found in the literature we
studied. For example in two studies [32,33] negative
results were reported, but no details given.
Our review is consistent with a general trend in appraising
the potential risk of oral cancer from use of smokeless
tobacco. In the mid 1980s smokeless tobacco was assessed
as a risk factor for oral cancer by IARC and the US Surgeon
General [10,11]. Although, according to an advance
report on a forthcoming monograph [81] IARC seems to
maintain this view, more recent reviews have reached dif-
ferent conclusions. Whereas tobacco chewing seems to be
a major risk factor for oral and pharyngeal cancer in Asia
[7] it is now considered unlikely to incur a substantial risk
among users of smokeless tobacco products in the United
States or Europe (e.g.[82]). The difference in risk between
Western smokeless tobacco products and those used in
developing countries may be related to tobacco species,
fermentation and ageing [83]. Also, the addition of ingre-
dients other than tobacco like betel quid, ash and lime
might play a role[12]. For Western tobacco, various
reviewers [84-86] have emphasized that any risk of life-
threatening diseases in general that is associated with
smokeless tobacco use is very much less than that associ-
ated with smoking. For example, Bates et al. [84] conclude
that "on average Scandinavian or some American smoke-
less tobaccos are at least 90% less hazardous than cigarette
smoking."
These reviews have led to discussion as to whether smoke-
less tobacco might be a less dangerous alternative to
smoking for those who do not quit [87-89]. Unlike in the
US, tobacco for oral use has been banned in all EU coun-
tries, except for Sweden, and a ban also exists in Switzer-
land. Fagerström and Schildt [90] refer to the low (and
declining) prevalence of smoking and the high (and
increasing) use of smokeless tobacco in Sweden, and sug-
gest this may be responsible for Sweden having the lowest
incidence of tobacco-related disease among developed
countries (see [89]). Fagerström and Schildt [90] report
that 47% of current snus users were former smokers and
28% of ex-smokers used snus at their last attempt to stop
smoking. An effect of snus use on smoking cessation was
also suggested by Gilljam & Galanti [91], who found that
the proportion of Swedish men that had ever used snus
was larger in former than current smokers (55 vs. 45%).
Discussing whether snus might be a gateway to smoking,
Fagerström and Schild [90] report that only 6% of daily
smokers had started tobacco consumption with snus.
They concluded that "on balance, there is reason to
believe that having snus available to the Swedish popula-
tion has been of benefit to public health." Whether or not
smokeless tobacco use can play a role in helping smokers
quit and reducing population risk overall has been fiercely
debated in recent years (e.g. [76,78]).
Conclusion
Detailed assessment of the overall risks and benefits of
smokeless tobacco use to public health requires consider-
ation of the whole spectrum of its possible health effects
and is beyond the scope of this review. While it is clear
that there are unique risks from smokeless tobacco use
(notably on non-malignant lesions of the oral mucosa
[92]), there are numerous reports that support the risks of
smoking-related diseases from smokeless tobacco as
being generally much less than those from smoking, as
was noted above. Although we deliberately refrain from
concluding here that smokeless tobacco products repre-
sent a lower overall disease risk alternative to cigarettes,
we do conclude from our findings that the available data
suggest at most a minor increased risk of oral cancer asso-
ciated with the use of a wide range of currently used West-
ern chewing tobacco and snuff. Observed associationsBMC Public Health 2007, 7:334 http://www.biomedcentral.com/1471-2458/7/334
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may well be due to confounding by smoking or alcohol
consumption. Any effect that increasing use of smokeless
tobacco use might have at the population level on risk of
oral cancer may depend more on the effect such an
increase might have on smoking or alcohol consumption
than on any direct effect of smokeless tobacco itself.
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